The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells

W. D. Mercer, Marc E Lippman, T. M. Wahl, C. A. Carlson, D. A. Wahl, D. Lezotte, P. O. Teague

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Indirect immunofluorescence and immunoperoxidase assays were developed to detect estradiol and progesterone in breast cancer cells. Appropriate controls were used to confirm immunologic specificity. Studies of estradiol binding by human breast cancer cells identified three groups: no detectable binding (25%); all tumor cells exhibiting binding although to different degrees (4%); and tumors with varying numbers of positive and negative cells (71%). Similar observations were made with respect to progesterone binding. The percentage of cells with estradiol binding was correlated with the amount of estrogen receptors (ER) present in the tumor specimens. Post-hormone binding events, e.g., nuclear binding of estradiol, were also evaluated. Some tumor cells showing cytoplasmic binding of estradiol did not show nuclear binding of estradiol; such tumors lacked detectable progesterone binding and progesterone receptors. Estradiol binding could not be competed with by diethylstilbestrol under routine assay conditions, and relatively high concentrations of estradiol were needed to observe estradiol-specific staining. The results suggest that the immunocytochemical assays detect hormone-specific binding, but that the binding is probably due to multiple classes of steroid-binding sites.

Original languageEnglish
Pages (from-to)2859-2868
Number of pages10
JournalCancer
Volume46
Issue number12 SUPPL.
StatePublished - Dec 1 1980
Externally publishedYes

Fingerprint

Estradiol
Steroids
Hormones
Breast Neoplasms
Progesterone
Neoplasms
Diethylstilbestrol
Progesterone Receptors
Indirect Fluorescent Antibody Technique
Estrogen Receptors
Binding Sites
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mercer, W. D., Lippman, M. E., Wahl, T. M., Carlson, C. A., Wahl, D. A., Lezotte, D., & Teague, P. O. (1980). The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. Cancer, 46(12 SUPPL.), 2859-2868.

The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. / Mercer, W. D.; Lippman, Marc E; Wahl, T. M.; Carlson, C. A.; Wahl, D. A.; Lezotte, D.; Teague, P. O.

In: Cancer, Vol. 46, No. 12 SUPPL., 01.12.1980, p. 2859-2868.

Research output: Contribution to journalArticle

Mercer, WD, Lippman, ME, Wahl, TM, Carlson, CA, Wahl, DA, Lezotte, D & Teague, PO 1980, 'The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells', Cancer, vol. 46, no. 12 SUPPL., pp. 2859-2868.
Mercer WD, Lippman ME, Wahl TM, Carlson CA, Wahl DA, Lezotte D et al. The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. Cancer. 1980 Dec 1;46(12 SUPPL.):2859-2868.
Mercer, W. D. ; Lippman, Marc E ; Wahl, T. M. ; Carlson, C. A. ; Wahl, D. A. ; Lezotte, D. ; Teague, P. O. / The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. In: Cancer. 1980 ; Vol. 46, No. 12 SUPPL. pp. 2859-2868.
@article{d9908e18baa24b08bcc2bd2517a3f40c,
title = "The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells",
abstract = "Indirect immunofluorescence and immunoperoxidase assays were developed to detect estradiol and progesterone in breast cancer cells. Appropriate controls were used to confirm immunologic specificity. Studies of estradiol binding by human breast cancer cells identified three groups: no detectable binding (25{\%}); all tumor cells exhibiting binding although to different degrees (4{\%}); and tumors with varying numbers of positive and negative cells (71{\%}). Similar observations were made with respect to progesterone binding. The percentage of cells with estradiol binding was correlated with the amount of estrogen receptors (ER) present in the tumor specimens. Post-hormone binding events, e.g., nuclear binding of estradiol, were also evaluated. Some tumor cells showing cytoplasmic binding of estradiol did not show nuclear binding of estradiol; such tumors lacked detectable progesterone binding and progesterone receptors. Estradiol binding could not be competed with by diethylstilbestrol under routine assay conditions, and relatively high concentrations of estradiol were needed to observe estradiol-specific staining. The results suggest that the immunocytochemical assays detect hormone-specific binding, but that the binding is probably due to multiple classes of steroid-binding sites.",
author = "Mercer, {W. D.} and Lippman, {Marc E} and Wahl, {T. M.} and Carlson, {C. A.} and Wahl, {D. A.} and D. Lezotte and Teague, {P. O.}",
year = "1980",
month = "12",
day = "1",
language = "English",
volume = "46",
pages = "2859--2868",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells

AU - Mercer, W. D.

AU - Lippman, Marc E

AU - Wahl, T. M.

AU - Carlson, C. A.

AU - Wahl, D. A.

AU - Lezotte, D.

AU - Teague, P. O.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - Indirect immunofluorescence and immunoperoxidase assays were developed to detect estradiol and progesterone in breast cancer cells. Appropriate controls were used to confirm immunologic specificity. Studies of estradiol binding by human breast cancer cells identified three groups: no detectable binding (25%); all tumor cells exhibiting binding although to different degrees (4%); and tumors with varying numbers of positive and negative cells (71%). Similar observations were made with respect to progesterone binding. The percentage of cells with estradiol binding was correlated with the amount of estrogen receptors (ER) present in the tumor specimens. Post-hormone binding events, e.g., nuclear binding of estradiol, were also evaluated. Some tumor cells showing cytoplasmic binding of estradiol did not show nuclear binding of estradiol; such tumors lacked detectable progesterone binding and progesterone receptors. Estradiol binding could not be competed with by diethylstilbestrol under routine assay conditions, and relatively high concentrations of estradiol were needed to observe estradiol-specific staining. The results suggest that the immunocytochemical assays detect hormone-specific binding, but that the binding is probably due to multiple classes of steroid-binding sites.

AB - Indirect immunofluorescence and immunoperoxidase assays were developed to detect estradiol and progesterone in breast cancer cells. Appropriate controls were used to confirm immunologic specificity. Studies of estradiol binding by human breast cancer cells identified three groups: no detectable binding (25%); all tumor cells exhibiting binding although to different degrees (4%); and tumors with varying numbers of positive and negative cells (71%). Similar observations were made with respect to progesterone binding. The percentage of cells with estradiol binding was correlated with the amount of estrogen receptors (ER) present in the tumor specimens. Post-hormone binding events, e.g., nuclear binding of estradiol, were also evaluated. Some tumor cells showing cytoplasmic binding of estradiol did not show nuclear binding of estradiol; such tumors lacked detectable progesterone binding and progesterone receptors. Estradiol binding could not be competed with by diethylstilbestrol under routine assay conditions, and relatively high concentrations of estradiol were needed to observe estradiol-specific staining. The results suggest that the immunocytochemical assays detect hormone-specific binding, but that the binding is probably due to multiple classes of steroid-binding sites.

UR - http://www.scopus.com/inward/record.url?scp=0019174351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019174351&partnerID=8YFLogxK

M3 - Article

C2 - 7004626

AN - SCOPUS:0019174351

VL - 46

SP - 2859

EP - 2868

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12 SUPPL.

ER -